We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 15, 2022

Updated Overall Survival Analysis of Erlotinib vs Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA EGFR+ NSCLC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer
J. Clin. Oncol 2022 Aug 26;[EPub Ahead of Print], D Yue, S Xu, Q Wang, X Li, Y Shen, H Zhao, C Chen, W Mao, W Liu, J Liu, L Zhang, H Ma, Q Li, Y Yang, Y Liu, H Chen, Z Zhang, B Zhang, C Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading